Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2) by Maher, TM et al.
  1Maher TM, et al. BMJ Open Resp Res 2019;6:e000422. doi:10.1136/bmjresp-2019-000422
To cite: Maher TM, Kreuter M, 
Lederer DJ, et al. Rationale, 
design and objectives of 
two phase III, randomised, 
placebo-controlled studies of 
GLPG1690, a novel autotaxin 
inhibitor, in idiopathic 
pulmonary fibrosis (ISABELA 
1 and 2). BMJ Open Resp Res 
2019;6:e000422. doi:10.1136/
bmjresp-2019-000422
 ► Additional material is 
published online only. To 
view please visit the journal 
online (http:// dx. doi. org/ 10. 
1136bmjresp- 2019- 000422).
Received 21 February 2019
Revised 23 April 2019
Accepted 2 May 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Toby M Maher;  
 t. maher@ rbht. nhs. uk
Rationale, design and objectives of two 
phase III, randomised, placebo-
controlled studies of GLPG1690, a novel 
autotaxin inhibitor, in idiopathic 
pulmonary fibrosis (ISABELA 1 and 2)
Toby M Maher,   1 Michael Kreuter,2 David J Lederer,3 Kevin K Brown,4 Wim Wuyts,5 
Nadia Verbruggen,6 Simone Stutvoet,6 Ann Fieuw,6 Paul Ford,6 Walid Abi-Saab,6 
Marlies Wijsenbeek7
Interstitial lung disease
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Introduction While current standard of care (SOC) 
for idiopathic pulmonary fibrosis (IPF) slows disease 
progression, prognosis remains poor. Therefore, an unmet 
need exists for novel, well-tolerated agents that reduce 
lung function decline and improve quality of life. Here we 
report the design of two phase III studies of the novel IPF 
therapy, GLPG1690.
Methods and analysis Two identically designed, phase 
III, international, randomised, double-blind, placebo-
controlled, parallel-group, multicentre studies (ISABELA 1 
and 2) were initiated in November 2018. It is planned that, 
in each study, 750 subjects with IPF will be randomised 
1:1:1 to receive oral GLPG1690 600 mg, GLPG1690  
200 mg or placebo, once daily, on top of local SOC, for at 
least 52 weeks. The primary endpoint is rate of decline of 
forced vital capacity (FVC) over 52 weeks. Key secondary 
endpoints are week 52 composite endpoint of disease 
progression or all-cause mortality (defined as composite 
endpoint of first occurrence of ≥10% absolute decline 
in per cent predicted FVC or all-cause mortality at week 
52); time to first respiratory-related hospitalisation until 
end of study; and week 52 change from baseline in the St 
George’s Respiratory Questionnaire total score (a quality-
of-life measure).
Ethics and dissemination Studies will be conducted 
in accordance with Good Clinical Practice guidelines, 
Declaration of Helsinki principles, and local ethical and 
legal requirements. Results will be reported in a peer-
reviewed publication.
Trial registration numbers NCT03711162; 
NCT03733444.
InTRoduCTIon
Idiopathic pulmonary fibrosis (IPF) is a 
chronic, progressive condition characterised 
by fibrosis, dyspnoea, worsening lung func-
tion and impaired quality of life (QoL).1 2 IPF 
is one of the most common forms of inter-
stitial lung disease,3 affecting approximately 
three million people worldwide.2 Patients are 
typically aged over 60 years at diagnosis4 and 
have a poor prognosis; the median survival 
is 3–4 years and the 5-year survival rate is 
20%–40%.1 5 Respiratory failure is the most 
common cause of death.6
During the last decade, significant 
advances have been made in understanding 
the complex biological mechanisms respon-
sible for IPF.1 7 It is currently accepted that 
chronic epithelial cell injury results in 
abnormal wound healing and widespread 
fibrosis, which replaces normal lung paren-
chyma.1 8 9 Consequently, treatment has 
moved from classical anti-inflammatory 
and immunosuppressant drugs to agents 
designed to inhibit the processes that drive 
fibrosis.1 7–9 Two antifibrotic agents, pirfeni-
done and nintedanib, were approved for 
Key messages
 ► Idiopathic pulmonary fibrosis (IPF) is associated with 
progressive loss of lung function and a median sur-
vival of 3–4 years.
 ► Standard of care (SOC) with the antifibrotic agents 
pirfenidone or nintedanib may slow disease pro-
gression; however, more effective, well-tolerated IPF 
treatments are needed.
 ► The autotaxin inhibitor, GLPG1690, is in development 
as a novel therapy for IPF and has demonstrated en-
couraging results in early clinical trials, warranting 
further studies.
 ► GLPG1690 in addition to SOC will be assessed in 
patients with IPF in ISABELA 1 and 2, two identically 
designed, phase III, randomised, placebo-controlled, 
parallel-group trials.
 ► The trials will provide valuable efficacy, safety and 
quality-of-life data, and positive findings may ulti-
mately lead to a much-needed new treatment option 
for patients with IPF.
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Screening First 52 weeks of study
As from 52 weeks
of study treatment
Follow-up
(4 weeks)
GLPG1690 600 mg q.d. (n=250)
GLPG1690 200 mg q.d. (n=250)
Placebo (n=250)
V1
V3
D1
V4
W2
V5
W4
V6
W8
V7
W12
V8
W18
V9
W26
V10
W34
V11
W42
V12
W52
Every 12 weeks
up to EoST/EoSA
EoST/
EoSA FU
V2
Figure 1 Design of the ISABELA 1 and 2 studies.  
D, day; EoSA, end-of-study assessment; EoST, end-of-
study treatment; FU, follow-up; qd, once daily; V, visit;  
W, week.
the treatment of IPF and included under conditional 
recommendations in 2015 clinical practice guide-
lines10 11 after demonstrating a reduction in lung func-
tion decline, measured by forced vital capacity (FVC), 
in phase III trials.12–14 Subsequent pooled analyses of 
phase III trials have shown reductions in mortality.14 15 
In addition, real-world registry data suggest improved 
survival in those treated with, versus without, antifibrotic 
treatments, regardless of baseline disease severity,16 
and pooled registry and clinical trial data suggest that 
pirfenidone increases life expectancy compared with 
best supportive care.17
However, individuals may not tolerate adverse events 
(AEs) associated with pirfenidone (gastrointestinal and 
skin-related events)12 14 or nintedanib (diarrhoea)13; 
real-world data showed that AEs led to drug discontin-
uation in 20.9% and 26.3% of pirfenidone-treated and 
nintedanib-treated patients with IPF, respectively.18 QoL 
is often significantly impaired in IPF,1 9 19 and neither 
pirfenidone nor nintedanib has demonstrated bene-
fits to QoL in clinical trials.20 21 While both agents may 
improve overall outcomes, treated patients continue 
to experience lung function loss and premature death. 
Therefore, new treatments are needed that reduce the 
decline in FVC to a greater degree than current thera-
pies, hopefully halting the disease or, better yet, reversing 
its course. New treatments, ideally, would also improve 
or slow the rate of decline in patient-reported outcomes 
(PROs), including QoL, and must have an acceptable 
safety and tolerability profile, allowing for chronic use.
The aberrant wound healing responses that result in 
fibrosis in IPF are thought to be at least partially mediated 
by lysophosphatidic acid (LPA).22 23 Levels of LPA and 
autotaxin (ATX), an enzyme involved in its production,24 
are upregulated in patients with IPF, confirming their role 
in disease pathogenesis and potential as targets for novel 
therapeutic agents.25 26 One such agent is GLPG1690 
(Galapagos NV, Mechelen, Belgium), a first-in-class, small 
molecule ATX inhibitor.27 In a phase I, first-in-human 
trial, GLPG1690 was generally well tolerated and resulted 
in a maximum reduction in plasma LPA levels of approxi-
mately 90%.28 In the phase IIa FLORA study, conducted in 
23 subjects with IPF, GLPG1690 exhibited a safety profile 
similar to placebo and demonstrated favourable effects on 
mean change from baseline in FVC at week 12 compared 
with placebo (25 mL vs –70 mL) (although the study was 
not powered to evaluate efficacy differences between 
groups).29
To further evaluate GLPG1690 for the treatment of 
IPF, two identically designed, phase III studies (ISABELA 
1 and 2) will be conducted. The primary objective of 
the studies is to evaluate the efficacy of two doses of 
GLPG1690 compared with placebo, each given in addi-
tion to local standard of care (SOC), in subjects with IPF, 
as assessed by the rate of decline of FVC over 52 weeks. 
Secondary objectives relate to efficacy, mortality, QoL, 
safety, tolerability and pharmacokinetics. Here we report 
the design of the studies.
METhodS And AnAlySIS
Study design and interventions
ISABELA 1 and 2 are identically designed, phase III, 
international, randomised, double-blind, placebo-con-
trolled studies that will be conducted in parallel. Within 
each country, the study may be conducted at multiple 
centres. A significant proportion of subjects are expected 
to be recruited from the USA and Europe (see  Clinical-
Trials. gov for location details).
In each study, approximately 750 subjects will be 
randomised 1:1:1 to receive oral GLPG1690 600 mg, 
GLPG1690 200 mg or matching placebo, once daily, 
in addition to local SOC. SOC is defined as either 
pirfenidone or nintedanib, or neither pirfenidone nor 
nintedanib (for any reason). Treatment will continue 
for at least 52 weeks (subjects will continue to receive 
randomised treatment until the last patient reaches 
52 weeks in the study). A follow-up visit will be conducted 
4 weeks after the end-of-study visit (figure 1).
Treatment will be allocated using a centralised elec-
tronic system (interactive web response system) and 
randomisation will be stratified by local SOC for IPF. 
Both subjects and study personnel will be blinded to 
treatment assignment. The blind can be broken only if 
deemed necessary for safety reasons by the investigator. 
GLPG1690 doses were selected based on efficacy, safety, 
tolerability, and pharmacokinetic and pharmacodynamic 
data from previous clinical and preclinical studies,28 29 
and are expected to allow plasma concentrations >80% 
inhibitory concentration of LPA to be attained for ≥60% 
of the dosing interval. Investigators may reduce the 
dose, interrupt or permanently discontinue GLPG1690 
for safety concerns at any point. Downtitration will be 
performed as a single step to reduce the dose to the lowest 
level. Re-escalation from the lowest dose to the original 
dose will be conducted in two steps using an interme-
diate dose. Subjects who discontinue early (unless lost to 
follow-up/withdrawal of consent) will be encouraged to 
complete the remaining visits and evaluations.
ISABELA 1 and 2 are registered on  ClinicalTrials. gov 
(NCT03711162 and NCT03733444, respectively). Enrol-
ment began in November 2018; both studies are currently 
open to recruitment.
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Patient population
Eligible subjects will be men or women aged ≥40 years 
diagnosed with IPF within the previous 5 years (based 
on applicable international guidelines11 30). IPF diag-
nosis will be confirmed by central reading of a chest 
high-resolution computed tomography performed 
within the previous 12 months, plus central reading 
of lung biopsy (if available), based on the Fleischner 
Society white paper.31 Subjects should be receiving local 
SOC, defined as a stable dose of either pirfenidone or 
nintedanib, for at least 2 months prior to screening, or 
neither pirfenidone nor nintedanib; and have an FVC 
≥45% predicted of normal, forced expiratory volume in 
1 s (FEV1):FVC ≥0.7, and diffusing capacity of the lung for 
carbon monoxide (DLCO) corrected for haemoglobin 
≥30% predicted of normal. Subjects will be excluded if 
they have had an acute IPF exacerbation (determined 
by the investigator) within the previous 6 months; lower 
respiratory tract infection requiring antibiotics within 
the previous 4 weeks; interstitial lung disease associated 
with known primary diseases, environmental exposures 
or drugs; a history of lung volume reduction surgery or 
lung transplant; a diagnosis of severe pulmonary hyper-
tension; or unstable cardiovascular, pulmonary or other 
disease within 6 months prior to screening or during the 
screening period. Full inclusion and exclusion criteria 
are included in box 1.
Endpoints
The primary endpoint is rate of FVC decline over 52 weeks. 
Key secondary endpoints are disease progression, defined 
as the composite endpoint of first occurrence of ≥10% abso-
lute decline in per cent predicted FVC (%FVC) or all-cause 
mortality at week 52; time to first respiratory-related hospi-
talisation until the end of the studies; and change from 
baseline in the St George’s Respiratory Questionnaire 
(SGRQ)32 total score at week 52. Other endpoints will 
capture additional efficacy, mortality, QoL, safety, pharma-
cokinetic, pharmacodynamic and biomarker data (box 2).
Key assessments
The assessment schedule is shown in online supplemen-
tary file table 1. Prebronchodilator spirometry will be 
performed at screening and throughout the treatment 
period to assess pulmonary function. Spirometers will be 
provided to study centres and used according to stand-
ards outlined in international guidelines.33 The param-
eters measured or calculated as part of the spirometry 
assessments will be FVC (mL) and %FVC, FEV1 (mL) 
and per cent predicted FEV1, FEV1:FVC ratio, and forced 
expiratory flow between 25% and 75% of exhaled volume. 
Predicted values will be calculated using the 2012 Global 
Lung Function Initiative equations.34 At specified time 
points during screening and treatment, the DLCO test, 
corrected for haemoglobin, will be performed according 
to local practice, with appropriate prediction formulas, 
and in line with international guidelines (study centres 
may use different prediction formulas, as appropriate 
based on the local method used to measure DLCO), and 
at-rest arterial oxygen saturation will be measured by pulse 
oximetry. PROs will be assessed during screening and at 
specified weeks during treatment using the EuroQoL 
5-Dimensions Questionnaire (EQ-5D),35 SGRQ, King’s 
Brief Interstitial Lung Disease (K-BILD) question-
naire,36 Leicester Cough Questionnaire (LCQ),37 and 
Visual Analogue Scale (VAS) Cough and Urge to Cough. 
PRO questionnaires will be completed electronically by 
subjects using a tablet device at clinical study centres. 
The 6-Minute Walk Test, performed using a standard-
ised manual designed based on clinical guidelines and 
published literature,38–40 will be used to assess pulmonary 
function at specified time points during screening and 
treatment periods. Safety will be assessed throughout via 
reporting of AEs, clinical laboratory evaluations, physical 
examination, vital signs and electrocardiogram. Other 
assessments will include pharmacokinetic, pharmacody-
namic, biomarker and genotype evaluations.
Statistical analyses
Primary and safety analyses will be performed on the 
full analysis set (all randomised subjects who received at 
least one dose of study drug). The primary time point 
is week 52; analyses conducted at the end of the studies 
are secondary or supportive. An interim analysis to assess 
futility will be conducted when a reasonable number of 
subjects (eg, 25% from the two studies combined) have 
completed 52 weeks of treatment. An independent data 
monitoring committee (IDMC) will review the interim 
analysis results and make a recommendation to the 
sponsor, who will remain blinded. The study will not be 
terminated early for positive interim efficacy results.
The rate of decline of FVC will be analysed using a 
random coefficient regression model including sex, age, 
height and stratification factor as covariates and a random 
slope and intercept. The proportion of subjects who have 
an absolute decline ≥10% in %FVC at least once during the 
study, or who die, will be analysed using logistic regression 
analysis using data up to week 52. A time-to-event analysis 
may be used to analyse the composite endpoint of %FVC 
decline and mortality up to the end of the studies. FVC and 
%FVC will be analysed by subgroups (eg, baseline charac-
teristics, background treatment and stratum).
Time-to-event data (including hospitalisations and 
mortality) will be presented as Kaplan-Meier estimates. 
In addition, a Cox proportional hazards model with 
terms for age, sex, height and stratum will be used to 
estimate and test hazard ratios for each dose compared 
with placebo. A mixed-effects model with treatment, time 
(as a categorical factor), time–treatment interaction and 
baseline total score as factors will be applied to the SGRQ 
total score, and descriptive statistics will be used for other 
PRO data.
Sensitivity analyses including multiple imputation 
methods and a per-protocol analysis will assess the impact 
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Box 1 Full inclusion and exclusion criteria
Inclusion criteria.
 ► Male or female aged ≥40 years.
 ► Diagnosis of IPF within 5 years prior to screening based on the ATS/ERS/JRS/ALAT guidelines.
 ► Chest HRCT performed within 12 months prior to screening and according to minimum requirements for IPF diagnosis by central review based on 
HRCT only (if no lung biopsy is available) or HRCT and lung biopsy. If no HRCT is available prior to screening, an HRCT can be performed at screening.
 ► Subjects receiving local SOC for IPF, defined as either pirfenidone or nintedanib, at a stable dose for at least 2 months prior to screening, or neither 
pirfenidone nor nintedanib.
 ► The total extent of fibrotic changes is greater than the extent of emphysema on the most recent HRCT scan (investigator-determined).
 ► Meeting all of the following criteria during the screening period:
 – FVC ≥45% predicted of normal.
 – FEV1:FVC ≥0.7.
 – DLCO corrected for Hb ≥30% predicted of normal.
 ► In a stable condition and suitable for study participation based on the results of a medical history, physical examination, vital signs, 12-lead ECG 
and laboratory evaluation.
 ► Estimated minimum life expectancy of at least 30 months for non–IPF-related disease in the opinion of the investigator.
 ► Male subjects and female subjects of childbearing potential agree to use highly effective contraception/preventive exposure measures.
 ► Able to walk at least 150 m during the 6MWT at screening visit 1; at visit 2, for the oxygen titration test, resting SpO2 should be ≥88% with a maxi-
mum of 6 L O2/min; during the walk, SpO2 should be ≥83% with 6 L O2/min or ≥88% with 0, 2, or 4 L O2/min.
 ► Able to read and complete the EQ-5D, SGRQ, LCQ, K-BILD questionnaire and VAS by themselves.
 ► Able to understand the importance of adherence, and willing to comply to study treatment, study procedures and requirements as per study protocol, 
including the concomitant medication restrictions.
Exclusion criteria.
 ► Investigator or other study staff or relative thereof who is directly involved in the conduct of the study.
 ► Any condition or circumstance that, in the opinion of the investigator, may make a subject unsuitable for inclusion or unlikely or unable to complete 
the study or comply with study procedures and requirements.
 ► Previous participation in a clinical study with GLPG1690.
 ► Known hypersensitivity to any of the investigational medicinal product’s ingredients or a history of a significant allergic reaction to any drug as 
determined by the investigator.
 ► Current immunosuppressive condition.
 ► Positive serology for hepatitis B (antigen) or C (antibody).
 ► History of malignancy within the past 5 years (except for carcinoma in situ of the uterine cervix, basal cell carcinoma of the skin that has been treated 
with no evidence of recurrence, prostate cancer that has been medically managed through active surveillance or watchful waiting, squamous cell 
carcinoma of the skin if fully resected, and ductal carcinoma in situ).
 ► Clinically significant abnormalities detected on ECG of either rhythm or conduction, a QTcF >450 ms or a known long QT syndrome.
 ► Currently taking medication known to be a substrate mainly metabolised by CYP2C8.
 ► Currently taking medication known to be strong inducers of CYP3A4, and also including St John’s wort.
 ► Currently taking medication known to be strong inhibitors of CYP3A4.
 ► Currently taking medication known to be potent inducers of P-gp.
 ► Currently taking medication known to be potent inhibitors of P-gp.
 ► Acute IPF exacerbation within 6 months prior to screening and/or during the screening period (investigator-determined).
 ► Lower respiratory tract infection requiring antibiotics within 4 weeks prior to screening and/or during the screening period.
 ► Interstitial lung disease associated with known primary diseases (eg, sarcoidosis and amyloidosis), exposures (eg, radiation, silica, asbestos and 
coal dust) or drugs (eg, amiodarone).
 ► History of lung volume reduction surgery or lung transplant. Note: being on a transplant list is allowed.
 ► Diagnosis of severe pulmonary hypertension (investigator-determined).
 ► Unstable cardiovascular, pulmonary (other than IPF) or other disease within 6 months prior to screening or during the screening period (eg, acute 
coronary disease, heart failure and stroke).
 ► Had gastric perforation within 3 months prior to screening and/or underwent major surgery within 3 months prior to screening or have major surgery 
planned during the study period.
 ► A history of being admitted to an institution under an administrative court order, if applicable by local legislation.
 ► Moderate to severe hepatic impairment (Child-Pugh B or C) and/or abnormal LFT at screening, defined as AST and/or ALT and/or total bilirubin ≥1.5× 
ULN, and/or GGT ≥3× ULN. Retesting is allowed once.
 ► Abnormal renal function defined as estimated creatinine clearance, calculated according to Cockcroft-Gault calculation <30 mL/min. Retesting is 
allowed once.
 ► Hb level <10 g/dL. Retesting is allowed once.
 ► Participation in a drug, device or biological investigational research study, concurrently with the current study, or within five half-lives of the agent 
(or within 8 weeks when half-life is unknown) prior to screening, or prior participation in an investigational drug antibody study within 6 months 
prior to screening.
Continued
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Box 1 Continued
 ► Use of any of the following therapies within 4 weeks prior to screening and during the screening period, or planned during the study: warfarin, 
imatinib, ambrisentan, azathioprine, cyclophosphamide, ciclosporin A, bosentan, methotrexate, sildenafil (except for occasional use), and prednisone 
at steady dose >10 mg/day or equivalent.
 ► Current alcohol or substance abuse in the opinion of the investigator.
 ► Pregnant, breastfeeding or planning to become pregnant or breastfeed during the study treatment or within 30 days after the last dose of investi-
gational medicinal product.
6MWT, 6-Minute Walk Test; ALAT, Latin America Thoracic Association; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ATS, American Thoracic Society; 
CYP, cytochrome P450; DLCO, diffusing capacity of the lung for carbon monoxide; ERS, European Respiratory Society; EQ-5D, EuroQoL 5-Dimensions Questionnaire; FEV1, 
forced expiratory volume in 1 s; FVC, forced vital capacity; GGT, gamma glutamyl transferase; Hb, haemoglobin; HRCT, high-resolution computed tomography; IPF, idiopathic 
pulmonary fibrosis; JRS, Japanese Respiratory Society; K-BILD, King’s Brief Interstitial Lung Disease; LCQ, Leicester Cough Questionnaire; LFT, liver function test; P-gp, 
P-glycoprotein; QTcF, QT interval corrected for heart rate using Fridericia’s formula; SGRQ, St George’s Respiratory Questionnaire; SOC, standard of care; SpO2, arterial 
oxygen saturation; ULN, upper limit of normal; VAS, Visual Analogue Scale.
of missing data, non-compliance and protocol violations 
on primary efficacy analyses. To account for multiple 
testing with respect to the primary endpoint within each 
study, due to two dose comparisons being compared with 
placebo, a Bonferroni approach will be applied to the 
alpha level with a focus on the higher dose. Using this 
approach, the GLPG1690 600 mg and 200 mg doses will 
be tested versus placebo at a 0.04 and 0.01 level, respec-
tively. A sample size of 250 per group will have 80% power 
to show a significant effect, assuming GLPG1690 600 mg 
has an effect ≥80 mL. Further details regarding the statis-
tical power of the studies are included in table 1.
Patient and public involvement
Patients or the public were not involved in the design of 
the studies, but may be involved in the reporting of the 
research.
Ethics and dissemination
All subjects will provide written informed consent (obtained 
by investigator/designated personnel) and a subject iden-
tification code list will ensure patient confidentiality. 
The IDMC will regularly assess potential safety risks and 
will also assess the effect of GLPG1690 on lung function, 
determined by rate of FVC decline, as part of a benefit–
risk evaluation. Based on interim futility analysis results, 
the IDMC will make recommendations to the sponsor 
regarding study progress. A clinical endpoint adjudication 
committee comprising an independent group of experts 
will review and adjudicate clinical endpoints in a blinded 
manner. Details regarding data dissemination are provided 
in online supplementary file 1.
dISCuSSIon
ISABELA 1 and 2, two identically designed, phase III 
studies, will provide efficacy, safety and QoL data from 
subjects with IPF treated with GLPG1690 in addition 
to local SOC. Although antifibrotic agents are recom-
mended for the treatment of IPF, approximately 40% 
of patients do not receive them.41 42 Furthermore, while 
both pirfenidone and nintedanib slow physiological 
disease progression, substantial declines in FVC still 
occur (–145 mL with pirfenidone in ASCEND43; –114.7 
mL and –113.6 mL with nintedanib in INPULSIS-1 and 
INPULSIS-2,13 respectively), neither benefits QoL, 
and while survival is likely prolonged by treatment 
with these agents, IPF-related mortality remains high 
and the majority of patients still die due to respira-
tory failure.44 Therefore, there is a need for novel 
IPF therapies that further prevent worsening in lung 
function, benefit QoL and improve life expectancy. 
In addition, therapies must have an acceptable safety 
and tolerability profile. Data from early clinical studies 
of GLPG1690 are encouraging.28 29 In the phase IIa 
FLORA study, GLPG1690 was generally well toler-
ated and preliminary efficacy signals were observed,29 
warranting further evaluation of the drug in a larger 
population, over a longer period.
ISABELA 1 and 2 will allow a wider range of subjects 
to be enrolled compared with previous phase III 
IPF clinical studies due to less restrictive eligibility 
criteria.12–14 For example, subjects in ISABELA 1 
and 2 must have an FVC ≥45% predicted of normal, 
whereas predicted FVC was required to be ≥50% in 
the CAPACITY and INPULSIS studies, and 50%–90% 
in the ASCEND study.12–14 In addition, unlike in 
CAPACITY and ASCEND, which excluded subjects 
aged >80 years,12 14 there is no upper age limit in 
ISABELA 1 and 2. The broad eligibility criteria mean 
that only subjects with very severe IPF will be excluded, 
more closely reflecting how the agent may be used in 
the real world. Furthermore, in contrast to previous 
phase III IPF trials, ISABELA 1 and 2 will evaluate 
GLPG1690 when added to local SOC. Such data are 
important as experience of late-stage clinical studies 
to evaluate IPF treatments as an add-on to background 
therapy is limited. With multiple pathways thought to 
be involved in the pathogenesis of IPF, combination 
therapy is a logical treatment approach. In addition, 
given the benefits of pirfenidone and nintedanib over 
placebo, future clinical trials will likely assess new IPF 
treatments as add-on therapies to these agents, and 
consequently combination regimens may become SOC 
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Box 2 Endpoints to be assessed
Primary endpoint.
 ► Rate of decline of FVC (in mL) over 52 weeks.
Key secondary endpoints.
 ► Disease progression defined as the composite endpoint of first occurrence of ≥10% absolute decline in per cent predicted FVC or all-cause mortality 
at 52 weeks.
 ► Time to first respiratory-related hospitalisation until EoS.
 ► Change from baseline in the SGRQ total score at 52 weeks.
other secondary endpoints.
 ► Rate of decline of FVC (in mL) until EoS.
 ► Disease progression defined as the composite endpoint of first occurrence of ≥10% absolute decline in per cent predicted FVC or all-cause mortality 
until EoS.
 ► Change from baseline in the SGRQ total score at EoS.
 ► Time to first all-cause non-elective hospitalisation until EoS.
 ► Time to respiratory-related mortality until EoS.
 ► Time to lung transplant until EoS.
 ► Time to first acute IPF exacerbation (determined by the clinical endpoint adjudication committee) until EoS.
 ► Time to all-cause mortality or lung transplant until EoS.
 ► Time to all-cause mortality, or lung transplant or qualifying for lung transplant until EoS.
 ► Time to all-cause mortality, ≥10% absolute decline in per cent predicted FVC or respiratory-related hospitalisations until EoS.
 ► Time to all-cause mortality or respiratory-related hospitalisations until EoS.
 ► FVC analyses at 52 weeks and until EoS:
 – Absolute and relative change from baseline of FVC and per cent predicted FVC.
 – Absolute categorical change of per cent predicted FVC until EoS: decrease by >5, increase by >5 and change within ≤5.
 – Absolute categorical change of per cent predicted FVC until EoS: decrease by >10, increase by >10 and change within ≤10.
 ► Safety and tolerability over time until EoS.
 ► Changes from baseline in cough-related quality of life, assessed by the LCQ total score and domains over time, and the VAS Cough and Urge to 
Cough at 52 weeks and until EoS.
 ► Changes from baseline in quality of life, assessed by the EQ-5D, K-BILD total score and domains over time at 52 weeks and until EoS.
 ► Plasma concentration of GLPG1690, pirfenidone and nintedanib (as appropriate) at 52 weeks and until EoS.
 ► Change from baseline in functional exercise capacity, assessed by the 6MWT distance, at 52 weeks and until EoS.
 ► Change from baseline in DLCO (corrected for Hb) at 52 weeks and until EoS.
other endpoints.
 ► Changes in target biomarkers/pharmacodynamics in blood over time compared with baseline until EoS.
 ► Changes in disease-specific biomarkers in blood over time compared with baseline until EoS.
 ► Efficacy and biomarker endpoints by genotype subgroups.
 ► Change from baseline in Borg Scale before and after 6MWT at 52 weeks and until EoS.
 ► Change from baseline in SpO2 until EoS.
6MWT, 6-Minute Walk Test; DLCO, diffusing capacity of the lung for carbon monoxide; EoS, end of study; EQ-5D, EuroQoL 5-Dimensions Questionnaire; FVC, forced vital 
capacity; Hb, haemoglobin; IPF, idiopathic pulmonary fibrosis; K-BILD, King’s Brief Interstitial Lung Disease; LCQ, Leicester Cough Questionnaire; SGRQ, St George’s 
Respiratory Questionnaire; SpO2, arterial oxygen saturation; VAS, Visual Analogue Scale.
in clinical practice.45 Nintedanib plus sildenafil was 
recently assessed in patients with IPF with DLCO ≤35% 
of predicted in the INSTAGE trial. However, no signifi-
cant difference in change from baseline in SGRQ total 
score versus nintedanib alone (the primary endpoint) 
was observed in this advanced patient population.46
ISABELA 1 and 2 will have a minimum treatment 
period of 52 weeks, allowing for long-term collection of 
blinded efficacy and safety data. Depending on recruit-
ment duration, a proportion of subjects will remain on 
study for substantially longer than 52 weeks, providing 
an opportunity to assess less frequently occurring clinical 
and safety events that may not be captured during studies 
with a conventional 1-year duration. A potential limitation 
of the ISABELA studies is that outcomes beyond 52 weeks 
will not be captured for all subjects. Furthermore, FVC 
data at week 52, a key element of the primary outcome, 
will likely be missing for a proportion of subjects; this 
is a limitation of trials in subjects with progressive, fatal 
diseases, such as IPF. The impact of missing data in the 
ISABELA trials will be assessed using sensitivity analyses. 
As IPF is a rare disease, recruiting the planned number 
of subjects may be difficult. In addition, GLPG1690 is not 
being evaluated against a specific comparator agent, and 
treatment in the comparator arms could change during 
the studies, making comparisons with existing SOC more 
challenging.
The studies include a wide range of endpoints 
allowing for the collection of clinically relevant 
data related to safety, tolerability, efficacy, mortality, 
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Table 1 Probability of statistical significance of zero, one or two treatment comparisons with placebo
mL 0 successful, % 1 successful, % 2 successful, % Power, %
∆600=80 ∆200=80 6.8 23.4 69.9 93.2
∆600=80 ∆200=60 10.1 46.9 43.0 89.9
∆600=80 ∆200=20 11.5 84.4 4.1 88.5
∆600=80 ∆200=0 11.2 88.0 0.7 88.8
∆600=90 ∆200=60 5.1 51.1 43.8 94.9
∆600=0 ∆200=0 95.2 4.5 0.3 4.8
Denoting ∆600 and ∆200, the true treatment differences of the two GLPG1690 treatment groups with placebo, and assuming a common 
standard deviation on the week 52 decline in forced vital capacity of 275 mL, the probability that zero, one or two of the treatment 
comparisons with placebo will be statistically significant and the power for each scenario are provided in the table.
A sample size of 250 patients in each treatment group will have at least 80% power to show a significant effect, assuming the GLPG1690 
600 mg group has a treatment effect of at least 80 mL in the overall population of treatment-naïve patients and patients on standard of care.
QoL, pharmacokinetics, pharmacodynamics and 
biomarkers. Given the potential challenge of enrolling 
subjects with a rare disease, it is advantageous to 
collect such an array of data from one study. Change 
in FVC over time, the studies’ primary endpoint, is an 
accepted surrogate for mortality, and a 10% decline in 
FVC is an indicator of disease progression, as reflected 
in certain key secondary endpoints.4 47 48 The inclusion 
of the EQ-5D, SGRQ, K-BILD questionnaire, LCQ, 
and VAS Cough and Urge to Cough endpoints allows 
for the assessment of treatment effects on PROs. 
While the key aim of treatment is to prevent disease 
progression, palliating symptoms and improving QoL 
are key aspects of IPF management.49 Conducting 
two identically designed studies in parallel enables 
outcomes to be confirmed between studies and allows 
for secondary data to be pooled, increasing the proba-
bility of detecting treatment effects.
ConCluSIonS
GLPG1690, the first ATX inhibitor in clinical develop-
ment for the treatment of IPF, will be evaluated in two 
parallel, identically designed, phase III studies (ISABELA 
1 and 2) with a 52-week minimum treatment period. For 
the first time, GLPG1690 will be assessed as an addition 
to SOC, reflecting potential real-world use. The studies 
will provide a wide range of clinically relevant data, 
building on positive clinical findings to date.28 29 Positive 
results may ultimately mean that GLPG1690, alone or in 
combination, will become a much-needed new treatment 
option for patients with IPF.—
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